A Phase II study of CA-702 in Patients with Sjogren's Syndrome

A Phase II Randomized, Placebo-controlled Double-blind study of CA-702 in Patients with Sjogren's Syndrome accompanied by xerostomia.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2073210083

Enrollment

Registered

2021-10-22

Start date

2021-10-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Sjogren's Syndrome

Interventions

locally Single injection of CA-702 or Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Diagnosed with primary Sjogren's Syndrome according to diagnostic criteria by Ministry of Health, Labour and Welfare Japan or ones by ACR- EULAR. - Have subjective symptom of xerostomia. - Amount of saliva assessed by Saxon's test is within a certain range. - Ineffectiveness or intolerance to existing drugs(muscarinic agonists)

Exclusion criteria

Exclusion criteria: Diagnosed with secondary Sjogren's Syndrome or suspected to be. Diagnosed with IgG4-related disease or suspected to be. Only anti-centromere antibodies are positive. Incapable of performing Saxon's test. Blood test related to virus infections is positive. Amount of saliva is suspected to be decreased by other than Sjogren's Syndrome. Have had injection of E-MNC already. Have participated in a clinical study of unapproved drug, medical product or medical device within 6-month before this study.

Design outcomes

Primary

Measure	Time frame
change in amount of saliva assessed by Saxon's test from baseline	—

Contacts

Public Contacttantou Chiken

CellAxia Inc.

ca702@cellaxia.com+81-3-3527-2448

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026